月份: 2026 年 4 月

PHILADELPHIA, PA, Apr 22, 2026 - (ACN Newswire via SeaPRwire.com) - Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a leader in AI-driven data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced the issuance of U.S. Patent No. 12,596,819 and Notices of Allowance on two additional U.S. patent applications. This milestone builds directly on the Company's December 2025 issuance of two foundational patents for blockchain-driven content licensing and tokenized monetization - further expanding its robust intellectual property portfolio headlined by the industry-defining Carbon Credit Tokenization Patent.Key Highlights for InvestorsOne newly issued patent and two Notices of Allowance extend protection across three high-value platforms: AI-validated data valuation & monetization, tokenized virtual location funding, and automated tax return preparation for digital assets and DeFi-directly addressing 1099-DA compliance challenges.Reinforces the Company's Sumerian® Crypto Anchors, DataValue®, DataScore®, and Information Data Exchange® (IDE®) technologies with quantum-resistant encryption and blockchain immutability, underpinning a growing pipeline of tokenization contracts and licensing deals.Arrives as the first full IRS Form 1099-DA filing season closes amid reported operational hurdles-including late deliveries by Coinbase, Kraken, and Gemini-demonstrating clear demand for Datavault AI's automated, tokenized tax solutions.Enabled use cases include tokenized commodities (copper, gold, precious metals), agricultural/genomic/healthcare data assets, NIL digital twins, funded virtual biotech marketplaces, and intelligent tax automation-integrating natively with the Company's edge GPU fleet and HPC infrastructure.Directly supports Datavault AI's 2026 revenue target of at least $200 million, accelerates commercialization across fintech, healthcare, biotech, energy, agriculture, sports & entertainment, and Web3, and opens new licensing and partnership opportunities.Scope of the Latest ProtectionsU.S. Patent No. 12,596,819 - "Method and System for Data Valuation and Secure Commercial Monetization Platform" (issued): Covers an end-to-end permissioned platform spanning opt-in data contribution, AI-driven automated valuation, blockchain-tokenized storage in the Datavault®, and trading on open exchanges with flexible compensation pathways (sales, licenses, rewards, charitable contributions).U.S. Patent Application No. 17/842,220 - "System and Method for Funding a Virtual Location" (Notice of Allowance): Protects the funding, authentication, and tokenized operation of organization-specific virtual locations, including multi-currency donations, integrated event and asset tokenization, portfolio-aligned advertising, and compensation mechanisms for data contributors.U.S. Patent Application No. 17/507,459 - "Platform and Method for Preparing a Tax Return" (Notice of Allowance): Covers automated tax return preparation for clients and employees, with specialized tokenized return handling for digital asset and DeFi activity, back-end form processing, and dynamic adjustment to evolving tax codes-precisely targeting the reconciliation burdens and visibility gaps plaguing the inaugural 1099-DA season.Market Context & TailwindsThe filings position Datavault AI at the convergence of three rapidly expanding markets. Tokenized real-world assets have already surpassed $30 billion in on-chain value (RWA.xyz 2025 data), with Boston Consulting Group and ADDX projecting the global market to exceed $16 trillion by 2030. The global data monetization market is forecast to grow from $7.53 billion in 2024 to $18.8 billion by 2033 (10.7% CAGR, SkyQuest Technology). The new tax-preparation patent arrives precisely as U.S. taxpayers navigate the first full season under the IRS Form 1099-DA digital asset broker reporting regime-where gross proceeds reporting began January 1, 2025, and basis reporting for certain transactions took effect January 1, 2026-amid well-documented industry friction around late broker filings and cross-wallet/chain/DeFi reconciliation.Investor Implications & Strategic OutlookCollectively, the issued patents and allowed applications extend IP coverage around innovations that transform raw data into tokenized, tradable assets and enable transparent funding, monetization, and automated tax handling of virtual environments and digital asset portfolios. These technologies are expected to integrate seamlessly with Datavault AI's anticipated edge GPU fleet and high-performance computing infrastructure, accelerating AI valuation processing and tokenization contract execution."Securing this issued patent and receiving Notices of Allowance on two additional applications validates our leadership in turning intangible data into verifiable, monetizable capital, and in enabling organizations to fund and operate virtual worlds with full transparency and user compensation," said Nathaniel T. Bradley, Founder and Chief Executive Officer of Datavault AI. "These filings deepen our competitive moat and accelerate our path to capturing meaningful share in the data asset, real-world asset, and digital asset tax-preparation markets-directly fueling our $200 million 2026 revenue target and expanding pipeline of tokenization contracts."For additional insight into Datavault AI's growth strategy, commercialization roadmap, and long-term vision for unlocking value from data and intellectual property through tokenization and licensing, investors are encouraged to view the recent Nasdaq interview with CEO Nathaniel Bradley, hosted by Tech Edge and now available at https://vimeo.com/1176174810About Datavault AI Inc.Datavault AI™ (NASDAQ:DVLT) is a pioneer in AI-driven data experiences, valuation, and monetization of assets in the Web 3.0 environment. The Company's cloud-based platform delivers comprehensive solutions across its Acoustic Sciences and Data Sciences divisions. Datavault AI's Acoustic Sciences division features WiSA®, ADIO®, and Sumerian® patented technologies for spatial and multichannel wireless, high-definition sound transmission. The Data Science Division harnesses Web 3.0 and high-performance computing to enable experiential data perception, valuation, and secure monetization across industries, including sports & entertainment, biotech, education, fintech, real estate, healthcare, energy, and more. The Information Data Exchange® (IDE®) is a token exchange technology powered by Nasdaq Financial Infrastructure. The Company owns and operates exchanges, including International Elements Exchange (IEE), Sports Illustrated Exchange (SIx), New York Interactive Advertising Exchange (NYIAX), and American Political Exchange (APE). The Company is headquartered in Philadelphia, PA. Learn more at https://www.dvlt.ai.Forward-Looking Statements: This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release, including statements regarding the Company's future operations, financial position, prospects, plans, objectives, expectations, and intentions, are forward-looking statements. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this release include, but are not limited to, statements regarding: (i) the ultimate issuance, scope, validity, and enforceability of U.S. Patent Application No. 17/842,220, U.S. Patent Application No. 17/507,459, and any related foreign or continuation applications; (ii) the commercial value, market adoption, and revenue contribution of the Company's patented and patent-pending technologies, including DataValue®, DataScore®, the Information Data Exchange® (IDE®), Sumerian® Crypto Anchors, and the Datavault® platform; (iii) the Company's ability to achieve its 2026 revenue target of at least $200 million; (iv) the Company's pipeline of tokenization contracts, licensing arrangements, and strategic partnerships; (v) the size, growth, and timing of the markets for tokenized real-world assets, data monetization, and digital-asset tax preparation; (vi) the integration and performance of the Company's anticipated edge GPU fleet and high-performance computing infrastructure; and (vii) the demand for automated tax-preparation solutions arising from IRS Form 1099-DA reporting requirements.These forward-looking statements are based on management's current expectations and assumptions and are subject to significant risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Such risks include, among others: the U.S. Patent and Trademark Office issuing claims narrower than those allowed or rejecting allowed claims on reexamination; delays or failures in commercializing the Company's patented and patent-pending technologies; the Company's ability to attract and retain customers, licensees, and exchange partners; competition from existing and emerging technologies; cybersecurity, blockchain protocol, and quantum-computing risks; changes in U.S. federal and state tax law affecting digital-asset reporting, including modifications to the Form 1099-DA regime; regulatory developments affecting digital assets, securities, data privacy, and tokenized real-world assets; the Company's ability to raise additional capital on acceptable terms; macroeconomic and capital-markets conditions; and the other risk factors discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings made with the U.S. Securities and Exchange Commission (the "SEC"), copies of which are available free of charge on the SEC's website at www.sec.gov.Except as required by applicable law, the Company undertakes no obligation, and expressly disclaims any duty, to update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances, or otherwise. Investors and security holders are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company gives no assurance that it will achieve its expectations. This release does not constitute an offer to sell, or the solicitation of an offer to buy, any security. Any forward-looking statements regarding potential acquisitions, dispositions, joint ventures, strategic alliances, licensing transactions, or similar arrangements are subject to the negotiation, execution, and consummation of definitive agreements and the satisfaction of customary closing conditions, and no assurance can be given that any such transaction will be completed on the terms contemplated, on the timing anticipated, or at all.Industry and Market Data: This press release contains industry, market, and competitive position data, including statistics, forecasts, and projections, that are based on or derived from independent industry publications, third-party research, surveys, and reports, including data attributed to RWA.xyz, Boston Consulting Group, ADDX, SkyQuest Technology, and the U.S. Internal Revenue Service. The Company has not independently verified the accuracy or completeness of any such third-party information and makes no representation or warranty, express or implied, as to its reliability. Industry publications and forecasts of this nature are inherently subject to assumptions, methodological limitations, and uncertainties, and projections, estimates, and beliefs based on such data may not prove to be accurate. Actual market size, growth rates, and the Company's position within these markets may differ materially from the figures presented herein.Trademarks, Trade Names, Service Marks and Copyrights: Datavault AI™, DataValue®, DataScore®, Information Data Exchange®, IDE®, Datavault®, WiSA®, ADIO®, and Sumerian® are trademarks, service marks, or registered trademarks of Datavault AI Inc. in the United States and/or other jurisdictions. This press release also refers to trademarks, service marks, trade names, and copyrights owned by other companies, including those of Coinbase, Kraken, Gemini, and Nasdaq. Solely for convenience, certain of the trademarks, service marks, trade names, and copyrights referred to in this press release may be listed without the ™, ®, ©, or SM symbols, but the Company will assert, to the fullest extent under applicable law, its rights to its own trademarks, service marks, trade names, and copyrights. The use or display of other parties' trademarks, service marks, trade names, or copyrights is not intended to and does not imply a relationship with, or endorsement or sponsorship by, the Company of any such third party.Media Contact:marketing@dvlt.aiInvestor Contact:Edward BargerVP Investor Relationsebarger@dvlt.ai | ir@dvlt.aiSOURCE: Datavault AI Inc Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

賓夕法尼亞州費城, 2026年4月22日 - (亞太商訊 via SeaPRwire.com) - Datavault AI Inc.（「Datavault AI」或「本公司」） （納斯達克代碼：DVLT），作為人工智慧驅動的數據變現、憑證認證、數位互動及實物資產（「RWA」）代幣化技術的領導者，今日宣布獲得美國專利第12,596,819號，並收到另外兩項美國專利申請的准予通知。此里程碑直接延續了本公司於2025年12月獲頒兩項關於區塊鏈驅動內容授權及代幣化變現的基礎專利，進一步擴展了其強大的智慧財產權組合，其中以定義業界標準的碳信用額度代幣化專利為首。投資者重點摘要一項新頒發的專利及兩份准予通知，將保護範圍延伸至三大高價值平台：AI驗證的數據估值與變現、代幣化虛擬地點融資，以及數位資產與去中心化金融（DeFi）的自動化報稅準備——直接解決1099-DA合規挑戰。透過量子抗性加密與區塊鏈不可篡改性，強化了公司的 Sumerian® 加密錨點、DataValue®、DataScore® 及 Information Data Exchange® (IDE®) 技術，為日益增長的代幣化合約與授權交易管道奠定基礎。此舉正值首個完整的 IRS 1099-DA 報稅季結束之際，期間據報出現諸多營運障礙——包括 Coinbase、Kraken 及 Gemini 的資料遲交問題——這充分顯示市場對 Datavault AI 自動化、代幣化稅務解決方案的明確需求。已實現的應用場景包括代幣化大宗商品（銅、黃金、貴金屬）、農業/基因組/醫療保健數據資產、NIL 數位孿生、資金支持的虛擬生物科技市場，以及智慧稅務自動化——這些功能皆能原生整合至該公司的邊緣 GPU 機隊與 HPC 基礎設施。此技術直接支持 Datavault AI 2026 年至少 2 億美元的營收目標，加速金融科技、醫療保健、生物科技、能源、農業、體育娛樂及 Web3 領域的商業化進程，並開拓新的授權與合作機會。最新專利保護範圍美國專利第 12,596,819 號 - 「數據估值與安全商業化變現平台的方法與系統」（已核准）：涵蓋端到端的許可制平台，包含自願參與的數據貢獻、AI驅動的自動化估值、在Datavault®中的區塊鏈代幣化儲存，以及透過開放式交易所進行交易並具備靈活的補償途徑（銷售、授權、獎勵、慈善捐贈）。美國專利申請號 17/842,220 - 「虛擬地點資金籌措系統與方法」（准予通知）：保護特定組織虛擬地點的資金籌措、驗證及代幣化運作，包括多幣種捐款、整合式活動與資產代幣化、與投資組合對應的廣告，以及針對資料貢獻者的補償機制。美國專利申請號 17/507,459 - 「報稅表製作平台與方法」（准予通知）：涵蓋針對客戶與員工的自動化報稅表製作，包含針對數位資產及 DeFi 活動的專用代幣化報稅處理、後端表單處理，以及對不斷演變稅法條文的動態調整——精準解決困擾首個 1099-DA 報稅季的對帳負擔與透明度缺口。市場背景與利多因素這些專利申請使 Datavault AI 處於三個快速擴張市場的交匯點。代幣化實體資產的鏈上價值已突破 300 億美元（RWA.xyz 2025 年數據），波士頓諮詢集團（BCG）與 ADDX 預測全球市場規模將於 2030 年前超過 16 兆美元。全球數據貨幣化市場預計將從 2024 年的 75.3 億美元成長至 2033 年的 188 億美元（年複合成長率 10.7%，SkyQuest Technology）。這項新的報稅專利問世之際，正值美國納稅人面臨國稅局（IRS）1099-DA表數位資產經紀商申報制度實施後的首個完整報稅季——其中總收入申報自2025年1月1日開始，特定交易的成本基礎申報則於2026年1月1日生效——而業界針對經紀商遲報以及跨錢包/鏈/DeFi對帳等問題的摩擦，早已廣為人知。對投資者的影響與戰略展望總體而言，已獲頒的專利及獲准的申請案，擴大了智慧財產權的涵蓋範圍，涵蓋將原始資料轉化為代幣化、可交易資產的創新技術，並能實現虛擬環境與數位資產組合的透明化資金籌措、變現及自動化稅務處理。預期這些技術將與 Datavault AI 計劃中的邊緣 GPU 機群及高效能運算基礎設施無縫整合，從而加速 AI 估值處理與代幣化合約的執行。「取得這項已核發專利，並收到另外兩項申請的准予通知，證實了我們在將無形數據轉化為可驗證、可變現資本方面的領導地位，以及在協助組織以完全透明且包含用戶補償的方式為虛擬世界提供資金與營運方面的優勢，」Datavault AI 創辦人暨執行長納撒尼爾·T·布拉德利（Nathaniel T. Bradley）表示。「這些專利申請深化了我們的競爭護城河，並加速了我們在數據資產、實體資產及數位資產稅務申報市場中搶佔重要市佔率的進程——這將直接推動我們達成 2026 年 2 億美元的營收目標，並擴展代幣化合約的業務管道。」若欲進一步了解 Datavault AI 的成長策略、商業化路線圖，以及透過代幣化與授權釋放數據及智慧財產權價值的長期願景，建議投資人觀看近期由 Tech Edge 主持、納斯達克（Nasdaq）對執行長納撒尼爾·布拉德利（Nathaniel Bradley）的專訪，該影片現已上線：https://vimeo.com/1176174810  關於 Datavault AI Inc.Datavault AI™（納斯達克代碼：DVLT）是 Web 3.0 環境中以人工智慧驅動的數據體驗、資產估值及變現領域的先驅。該公司基於雲端的平台透過其聲學科學與數據科學兩個部門，提供全面的解決方案。Datavault AI 的聲學科學部門擁有 WiSA®、ADIO® 及 Sumerian® 等專利技術，專注於空間與多聲道無線高解析度聲音傳輸。數據科學部門則運用 Web 3.0 及高效能運算技術，為體育娛樂、生物科技、教育、金融科技、房地產、醫療保健、能源等各產業提供體驗式數據感知、估值及安全變現服務。Information Data Exchange® (IDE®) 是一項由納斯達克金融基礎設施（Nasdaq Financial Infrastructure）驅動的代幣交易技術。本公司擁有並營運多項交易所，包括國際元素交易所（IEE）、運動畫刊交易所（SIx）、紐約互動廣告交易所（NYIAX）及美國政治交易所（APE）。本公司總部位於賓夕法尼亞州費城。更多資訊請瀏覽 https://www.dvlt.ai 。前瞻性陳述：本新聞稿包含《1933年證券法》（經修訂）第27A條、《1934年證券交易法》（經修訂）第21E條，以及《1995年私人證券訴訟改革法》所定義之「前瞻性陳述」。本新聞稿中除歷史事實陳述以外的所有陳述，包括關於本公司未來營運、財務狀況、前景、計畫、目標、預期及意圖之陳述，均屬前瞻性陳述。諸如「預期」、「相信」、 「可能」、「估計」、「預期」、「意圖」、「或」、「計劃」、「潛在」、「預測」、「預估」、「應」、「目標」、「將」、「會」等詞彙及類似表述，旨在識別前瞻性陳述，儘管並非所有前瞻性陳述均包含此類識別詞彙。本新聞稿中的前瞻性陳述包括但不限於以下內容：(i) 美國專利申請號 17/842,220、美國專利申請號 17/507,459 及任何相關外國或延續申請的最終核發、範圍、有效性及可執行性； (ii) 本公司已獲專利及專利申請中技術的商業價值、市場採用情況及營收貢獻，包括 DataValue®、DataScore®、Information Data Exchange® (IDE®)、Sumerian® Crypto Anchors 以及 Datavault® 平台； (iii) 本公司能否達成 2026 年至少 2 億美元的營收目標；(iv) 本公司代幣化合約、授權協議及戰略合作夥伴關係的進展； (v) 實體資產代幣化、數據變現及數位資產稅務申報市場的規模、成長與時機；(vi) 本公司預期部署的邊緣 GPU 機隊與高效能運算基礎設施之整合與表現；以及 (vii) 因應美國國稅局 1099-DA 表格申報要求所衍生的自動化稅務申報解決方案需求。這些前瞻性陳述係基於管理層當前的預期與假設，並受重大風險、不確定性及其他因素影響，可能導致實際結果與所表達或暗示者存在重大差異。此類風險包括但不限於：美國專利商標局在重新審查時頒發的專利範圍較原核准範圍更窄，或駁回已核准的專利主張；本公司專利及專利申請中技術的商業化進程延遲或失敗；本公司吸引及留住客戶、被授權人及交易所合作夥伴的能力；來自現有及新興技術的競爭； 網路安全、區塊鏈協議及量子運算風險；影響數位資產申報的美國聯邦及州稅法變更，包括對 1099-DA 表格制度的修改；影響數位資產、證券、資料隱私及代幣化實體資產的監管發展； 本公司能否以可接受的條款籌集額外資金；宏觀經濟及資本市場狀況；以及本公司截至 2025 年 12 月 31 日止財政年度之 10-K 表年度報告、後續 10-Q 表季度報告、 以及向美國證券交易委員會（「SEC」）提交的其他文件中討論之「風險因素」章節所載之其他風險因素，該等文件的副本可於 SEC 網站 www.sec.gov 免費取得。除適用法律要求外，本公司無義務且明確聲明不承擔任何責任，無論基於新資訊、未來事件、情況變更或其他原因，均不對任何前瞻性陳述進行更新或修訂。投資者及證券持有人應注意，切勿過度依賴此等前瞻性陳述，該等陳述僅反映本新聞稿發布當日的狀況。本公司不保證將實現其預期目標。本新聞稿不構成出售任何證券之要約，亦不構成購買任何證券之要約邀請。任何關於潛在收購、處分、合資企業、戰略聯盟、授權交易或類似安排之前瞻性陳述，均須待最終協議之協商、簽署及完成，並須滿足慣常之交割條件；且無法保證任何此類交易將按預期條款、預期時間完成，或能否完成。產業與市場數據：本新聞稿包含產業、市場及競爭地位數據，包括統計數據、預測及推算，該等數據係基於或源自獨立產業出版物、第三方研究、調查及報告，其中包含歸因於 RWA.xyz、波士頓諮詢集團（Boston Consulting Group）、ADDX、SkyQuest Technology 及美國國稅局（U.S. Internal Revenue Service）之數據。本公司並未獨立核實任何此類第三方資訊的準確性或完整性，且不就其可靠性作出任何明示或暗示的陳述或保證。此類行業出版物及預測本質上受制於假設、方法論限制及不確定性，基於該等數據所作的推算、估計及判斷可能無法被證實為準確。實際市場規模、增長率以及本公司在這些市場中的地位，可能與本文所述數據存在重大差異。商標、商號、服務標誌及著作權：Datavault AI™、DataValue®、DataScore®、Information Data Exchange®、IDE®、Datavault®、WiSA®、ADIO® 及 Sumerian® 均為 Datavault AI Inc. 於美國及／或其他司法管轄區的商標、服務標誌或註冊商標。本新聞稿亦提及其他公司所擁有的商標、服務標誌、商號及著作權，包括 Coinbase、Kraken、Gemini 及 Nasdaq 所擁有的相關標識。僅為方便起見，本新聞稿中提及的某些商標、服務標誌、商號及著作權可能未標示 ™、®、© 或 SM 符號，但本公司將在適用法律允許的最大範圍內，主張其對自身商標、服務標誌、商號及著作權的權利。使用或展示其他方的商標、服務標誌、商號或著作權，並非意在亦不暗示本公司與任何該等第三方存在關係，或獲得其背書或贊助。媒體聯絡人：marketing@dvlt.ai 投資人聯絡：Edward Barger投資人關係副總裁ebarger@dvlt.ai | ir@dvlt.ai 消息來源：Datavault AI Inc Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月22日 - (亞太商訊 via SeaPRwire.com) - 國內具有領先地位的城市燃氣營運商中國燃氣控股有限公司（「中國燃氣」或「集團」；股票編號：384）宣佈與中信建設有限責任公司（「中信建設」）及中信銀行股份有限公司（「中信銀行」）簽署戰略合作協議，三方將基於「資源共享、優勢互補、利益共用、互利共贏」的原則，構建「產、建、融」三位一體的生態式協同模式，進一步支持中國燃氣儲能及生物質能源等新業務發展，共同深耕全球能源基礎設施及綠色低碳產業。中國燃氣、中信建設及中信銀行正式簽署三方戰略合作協議此次合作是各方積極響應國家「十五五」規劃、深度參與「一帶一路」建設的重要舉措。根據協議，三方將建立全面戰略合作夥伴關係，在海外能源基礎設施建設、第三方項目聯合開發、產業園區業務、綠色金融及各類融資合作等領域展開深度合作，確立了「生態式協同」的閉環合作模式：即由中國燃氣作為商業模式主導方，負責項目策劃、技術方案與運營；中信建設作為工程建設實施方，發揮屬地資源調配與施工管理優勢；中信銀行作為金融服務提供方，解決投融資需求。三方將聚焦於多項核心領域展開深度合作，共同應對全球氣候變化及能源安全挑戰，包括：1）三方將重點聚焦欧洲、東南亞、中亞及北亞等潛力地區，共同推動能源基礎設施的開發與建設；2）圍繞中國燃氣於海內外主導開發的產業園區及新型城鎮化項目，三方將實現資源融合；3）三方將共同努力落實「綠色發展」戰略，並在投融資領域開展深度聯動。為把握全球能源轉型與國家「雙碳」目標機遇，集團正加快發展以儲能為核心的新能源業務及生物質能源業務兩大新增長極。在儲能領域，集團搶抓電力市場改革與新型電力系統建設的戰略機遇，持續深耕市場、優化佈局，呈現出「核心區域集中發力、海外市場重點突破」的態勢。另一方面，集團積極佈局生物質業務，實現多點開花，此前已與奇瑞汽车旗下得壹能源及億緯鋰能等多家龍頭企業及地方政府達成合作，共同推進零碳園區建設與產業清潔化升級。此次三方合作，將進一步助力集團開拓海内外市場，聚焦「儲能+生物質能」兩大新增長極，推動集團健康、可持續發展。集團主席兼總裁劉明輝先生表示：「中國燃氣經過二十餘年的發展，已構建起以天然氣為核心，融合LNG、LPG、生物質能源及新能源技術應用的全業態發展格局。當前，集團正加速全球化戰略，在歐洲、東南亞、中亞及北亞等地區已形成清晰的業務佈局。此次與中信建設、中信銀行達成三方協議，標誌著我們從單純的業務出海升級為『產業主導、工程賦能、金融助力』的集群式出海。通過與合作方金融與實業雙引擎的深度協同，我們將以更強的抗風險能力和全產業鏈優勢，為全球能源的可持續發展貢獻中國燃氣解決方案。」有關中國燃氣控股有限公司中國燃氣控股有限公司（「中國燃氣」，股票代號：384）是一家領先的燃氣運營服務商，主要於中國從事投資、建設、經營城市燃氣管道基礎設施，向居民及工商業用戶輸送天然氣和液化石油氣，建設和經營車船用天然氣加氣站。目前中國燃氣在全國已擁有662個城鎮的管道燃氣專營權項目、32個天然氣長輸管道項目、485座壓縮/液化天然氣汽車與船用加氣站，並擁有120個液化石油氣分銷項目。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

吉隆坡，2026年4月22日 - (亞太商訊 via SeaPRwire.com) - 萬利集團（以下簡稱「萬利」或「集團」）之上市實體 CBL International Limited（以下簡稱「公司」或「CBL」）（美國納斯達克交易所代碼：BANL），亞太地區知名燃油供應服務商，今日宣佈收購英屬維爾京群島註冊公司綠燃控股有限公司（「綠燃」）50.5%的多數股權。CBL的全資子公司作為《股份出售及購買協定》（簡稱「SPA」）的直接簽約方，而CBL並非該協議的簽約方，因此CBL向賣方提供公司擔保，以確保其子公司履行SPA下的付款義務。綠燃在馬來西亞經營兩項互補業務：可持續航空燃料（SAF）和生物燃料的原料貿易，以及船舶生物燃料供應並提供傳統燃料油加注服務。其原料貿易部門持有需的國際認證資格，以進行SAF及生物燃料生產所需原材料的採購和交易，並擁有成熟的供應商與客戶網路。至於燃料油加注業務方面，綠燃持有當地政府發出的許可證，可於馬來西亞水域供應傳統船用燃料及生物燃料。此次戰略投資符合全球日益重視環境、社會和治理（ESG），以及海事、航空領域監管要求持續強化所帶來的趨勢。CBL的財務資源及船用燃料物流運營專長，預計將助力綠燃業務的擴張，使其能進一步擴大原料貿易規模，並探索向馬來西亞SAF相關生產企業供應原材料的業務。馬來西亞可持續燃料的基礎設施投資持續增加。該國已有新的商業規模SAF生產設施投入運營，並有更多專案正規劃中。這些發展進一步突顯該地區對原料的潛在需求。在燃料油加注業務方面，綠燃所持的供應資格使集團得以在馬來西亞主要港口(包括巴生港) 進一步發展傳統燃料和生物燃料的供應能力。巴生港是全球輸送量前十的港口之一。上述能力將依託CBL現有的燃料油加注服務，支持航運業邁向低碳船用燃料轉型。CBL集團主席兼行政總裁謝威廉博士評論道：「此次收購是在可持續能源供應鏈上採取穩健拓展的一步，並充分利用了我們在船用燃料服務方面的核心優勢。 我們期待與綠燃團隊合作，支持這些業務按照市場發展實現負責任增長。」此次交易預計將增強CBL在不斷演變的海洋與能源領域的長期定位，同時不會改變公司對現有加燃料服務業務的核心專注。關於萬利集團萬利集團成立於2015年，以 CBL International Limited（納斯達克：BANL）在納斯達克股票市場上市。我們致力於為客戶提供一站式燃油供應服務，被業內稱為燃油供應服務商。截至2026年4月17日，我們主要通過當地實體供應商為船舶提供燃油加注服務，遍佈澳大利亞、比利時、中國、香港、印度、日本、韓國、馬來西亞、模里裘斯、荷蘭、巴拿馬、菲律賓、新加坡、臺灣、泰國、土耳其和越南，共覆蓋超過70個港口。 集團積極推動可持續燃料的使用，並已取得ISCC EU 和ISCC Plus認證，以及EcoVadis銀牌。如欲瞭解更多信息，請到集團網站 https://www.banle-intl.com 瀏覽。前瞻性聲明本公告中的某些陳述並非歷史事實，而是前瞻性陳述。 前瞻性陳述一般使用"相信"、"可能"、"可以"、"將要"、"估計"、"繼續"、"預期"、"打算"、"期望"、"計劃"、"應該"、"將會"、"未來"、"展望"、"潛力"、"專案"等類似詞語來預測或表達未來事件或趨勢或不屬於歷史事項的陳述，但不使用這些詞語並不意味著陳述並非前瞻性。 這些前瞻性陳述包括但不限於對其他績效指標的估計和預測，以及對市場機會的預測。 這些資訊涉及已知和未知的風險和不確定性，並基於各種假設（無論本新聞稿中是否指明）以及BANL管理層的當前預期，而非對實際業績的預測。 這些前瞻性陳述僅供說明目的，不得被任何投資者作為且不得被依賴為對事實或可能性的擔保、保證、預測或確鑿陳述。 實際事件和情況難以或不可能預測，也會與假設不同。 許多實際事件和情況不在BANL的控制範圍內。 一些重要因素可能導致實際結果與任何前瞻性陳述存在實質性差異，包括國內外商業、燃料價格及關稅、市場、金融、政治和法律環境的變化。 公司沒有義務公開更新或修改任何前瞻性陳述來反映隨後發生的事件或情況或預期的變化，除非法律要求。 儘管公司認為該等前瞻性陳述中表達的預期合理，但不能向您保證此類預期最終正確無誤。 公司提醒投資者實際結果可能與預期結果存在重大差異，並鼓勵投資者細閱公司的註冊聲明和向SEC提交的其他檔所載可能影響其未來業績的其他因素。CBL INTERNATIONAL LIMITED（註冊於開曼群島的有限責任公司）如需更多信息，請聯繫：CBL International Limited電郵：investors@banle-intl.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Brisbane, Queensland, Australia--(ACN Newswire via SeaPRwire.com - April 22, 2026) - Graphene Manufacturing Group Ltd (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that Stuart Watson — former global Head of Technical Development for Rio Tinto Ltd. (ASX: RIO), one of the largest mining and mineral production companies in the world, has joined GMG as Chief Production Growth Officer.Stuart has over 30 years of global leadership experience in metals and mining and oil and chemicals, including 20 years at Rio Tinto, across operations, sales and marketing, mergers and acquisitions, and technology development and innovation. Career highlights include:Leading and delivering multiple major transformation programs valued over US$5 Billion and merger and acquisition deals valued at US$1 Billion.Directing US$1 Billion in global technology and research & development spend to create breakthrough growth options and projectsBuilding high-performing global teams across Asia, Europe, and North AmericaStuart has a Master of Business Administration (MBA) - Henley Management College, UK; is a Chartered Engineer - Institute of Chemical Engineers (IChemE), has a Masters of Engineering, Chemical Engineering (First Class Honours) — Imperial College, University of London and Ecole Nationale Supérieure d'Ingénieurs de Génie Chimique (ENSIGC), Toulouse, France.Craig Nicol, CEO & Managing Director of the Company, commented "We welcome Stuart to the GMG team - he is a great addition to the Senior Executive Team for both executive leadership and delivery capability. I will enjoy working with Stuart to expand our production across our graphene and graphene products around the world."Jack Perkowski, Non-Executive Chairman and Director of the Company, commented: "On behalf of the board I welcome Stuart to the team and look forward to the progress around expanding our production capability into North America."Operations UpdateGMG is focused on delivering its Gen 2.0 Graphene Production Project (the "Gen 2.0 Project") by end of June 2026 — which is expected to produce at least 10 tonnes per annum of graphene at its headquarters in Richlands, Queensland, Australia.Once the Gen 2.0 Project is commissioned and operating. GMG plans to replicate and establish other production plants around the world to enable scaled production for potential sales, diversify and lower production risks, and in the end, reduce operating costs by locating the plant in countries with lower operating costs, including low cost natural gas — one of GMG's key production input costs.Currently, GMG is planning three potential expansion projects — two in North America (potentially one in US and one in Canada) in addition to an expansion production project in Australia. GMG proposes to mature these projects and expand production in line with sales for all of its products.The expansion program for GMG includes the following 5 production plants:Graphene Production (from natural gas)Coating Blend Plant (for the graphene coating THERMAL-XR®)Lubricant Blend Plant (for the graphene lubricant additive G® LUBRICANT)Graphene Slurry Plant (for the SUPA G Lithium-Ion Battery Additive)Battery Assembly Plant (for the Graphene Aluminium Ion Battery)Figure 1To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/293781_d1c07d1d84356a2d_001full.jpgAbout GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed at improving the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and U.S. securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "believes" "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements as to GMG's focus on, and the timing and production expectations of, the Gen 2 Project, intentions regarding the number, purpose and location of expansion projects, intentions to de-risk and develop commercial scale-up capabilities, GMG's focus in the energy savings segment, GMG's intentions for the use of graphene lubricant additive on saving liquid fuels, expectations for R&D and commercialization of G+AI Batteries, GMG's ability to improve the performance of lithium-ion batteries and GMG's critical business objectives.Such forward-looking statements are based on a number of assumptions of management, including the patent and potential market size of G® LUBRICANT. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation that GMG does not receive or receive on a timely basis the fully signed consent notice from the and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 4, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/293781 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Transaction will create a global powerhouse for mining finance and reduce complexity and costs for Canadian market participantsAcquisition will strengthen TMX's ability to serve clients across the capital markets ecosystem, expands global presence, accelerates growth strategyAnalyst webcast and conference call on Wednesday, April 22, 2026 at 8:00am EDT to discussToronto, Ontario--(ACN Newswire via SeaPRwire.com - April 22, 2026) - TMX Group Limited (TSX: X) (TMX Group) announced today an agreement to acquire Middlebury Holdings Pty. Limited (Cboe Australia) and Cboe Canada Holdings, ULC (Cboe Canada) from Cboe Global Markets, Inc. for US$300 million ($409 million*) in total consideration, a transaction that will bolster TMX's ability to serve clients across the capital markets ecosystem, expand the company's global presence, and accelerate the company's growth strategy, while reducing cost and complexity for Canadian market participants."We are tremendously excited to announce the acquisition of Cboe Australia and Cboe Canada, a deal that represents a unique opportunity to strengthen our domestic marketplace for clients and the entire stakeholder ecosystem, while expanding the reach and impact of our presence in a region of the world we know well," said John McKenzie, Chief Executive Officer, TMX Group. "We look forward to working with our industry partners to ensure a smooth transition, and to exploring innovative ways to serve the needs of issuers and investors across the Australian market, while continuing to seek out opportunities to accelerate our enterprise growth strategy."Cboe Australia and Cboe Canada offer equities trading venues, listing venues and market data solutions. Cboe Australia is an innovative securities exchange offering companies strategic tailored support for public market listings, including ETFs, as well as structured products and warrants, and providing a trading venue for brokers and investors with efficient and cost-effective access to local and global investment opportunities. Cboe Australia was also recently granted a license for corporate listings. Cboe Canada includes MATCHNow, NEO-L, NEO-N, and NEO-D, as well as ETF, CDR and corporate listings."The teams at Cboe Australia and Cboe Canada have delivered consistent performance and built resilient, high-quality markets," said Craig Donohue, Chief Executive Officer, Cboe Global Markets. "These businesses are well positioned for their next chapter, and we will work closely with TMX, our local regulators, and our clients to ensure a seamless transition."Transaction HighlightsTMX's acquisition of Cboe Australia will bring together the world's leading mining and energy transition financing ecosystems, unlocking potential to innovate for a growing global client base.TMX's acquisition of Cboe Canada enhances the quality of client experience across domestic equities marketplaces:Increasing efficiency of access to capital and liquidity for Canadian issuers, andReducing direct and indirect costs for participants, while improving execution quality and resiliency.Transaction expected to be accretive to adjusted earnings per share within the first 12 months of closing, excluding synergies.Revenue growth expected to be in-line with TMX's long-term financial objectivesCombined Cboe Canada and Cboe Australia businesses delivered revenue of approximately $87 million in 2025, and adjusted EBITDA of approximately $25 million**.Further Transaction DetailsThe purchase of each business is subject to regulatory approvals and customary closing conditions in Australia and Canada. The two components of this acquisition, Cboe Australia and Cboe Canada, are expected to close separately, each after required approvals have been obtained.Canaccord Genuity and Macquarie Capital are acting as financial advisors to TMX Group. FGS Longview is acting as strategic communications advisor to TMX Group.*Based on USD/CAD exchange rate of 1.3644 at April 21, 2026. Actual amounts in Canadian dollars are subject to change.**Based on average AUD/CAD of 0.90 for 2025. Cboe Australia and Canada revenue and EBITDA are compilations of financial information provided to us for the Cboe entities as of December 31, 2025. The Cboe financial information is unaudited and prepared in accordance with IFRS (Cboe Canada) or Australian Accounting Standards (Cboe Australia) for public companies.Teleconference / Audio WebcastTMX Group will host a teleconference / audio webcast to discuss the transaction.Time: 8:00 a.m. - 9:00 a.m. ET on Wednesday, April 22, 2026Participants may access the conference call via the webcast link: https://www.gowebcasting.com/14669.The audio webcast of the conference call and investor presentation will also be available on TMX Group's website at www.tmx.com, under Investor Relations.Alternatively, participants may join the live call by dialing 1-833-752-4317 or 1-647-846-2266.An audio replay of the conference call will be available at 1-855-669-9658 or 1-412-317-0088, [access code 6830744].Caution Regarding Forward-Looking InformationThis press release of TMX Group Limited ("TMX Group", "us", "we", "our") contains "forward-looking information" (as defined in applicable Canadian securities legislation) that is based on expectations, assumptions, estimates, projections and other factors that management believes to be relevant as of the date of this press release. Often, but not always, such forward-looking information can be identified by the use of forward-looking words such as "plans", "expects", "projects", "is expected", "projected", "budget", "scheduled", "targeted", "estimates", "forecasts", "intends", "anticipates", "believes", or variations or the negatives of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved or not be taken, occur or be achieved. Forward-looking information, by its nature, requires TMX Group to make assumptions and is subject to significant risks and uncertainties which may give rise to the possibility that our expectations or conclusions will not prove to be accurate and that our assumptions may not be correct. Examples of forward-looking information in this press release include, but are not limited to, the anticipated benefits of the transactions to TMX Group, Cboe Canada and Cboe Australia; the expected impact on TMX Group's earnings and Adjusted earnings per share; expectations regarding the revenue growth of Cboe Canada and Cboe Australia; the ability to integrate Cboe Canada and Cboe Australia into TMX Group and the potential synergies; the expected impact on TMX's long-term growth strategy and transformational objectives; the potential for geographic expansion; the ability for TMX Group to accelerate Cboe Canada and Cboe Australia's growth; the timing and receipt of regulatory approval; and closing of the transaction, each of which is subject to a number of significant risks and uncertainties. These risks include, but are not limited to: competition from other exchanges or marketplaces, including alternative trading systems and new technologies, on a national and international basis; dependence on the economies of Canada, the United States and Australia; adverse effects on our results caused by global economic conditions (including geopolitical events, interest rate movements or threats of recession) or uncertainties including changes in business cycles that impact our sector; failure to retain and attract qualified personnel; geopolitical and other factors which could cause business interruption; dependence on information technology; vulnerability of our networks and third party service providers to security risks, including cyber attacks; failure to properly identify or implement our strategies; regulatory constraints; constraints imposed by our level of indebtedness, risks of litigation or other proceedings; dependence on adequate numbers of customers; failure to develop, market or gain acceptance of new products; failure to close and effectively integrate acquisitions, including the Cboe Canada and Cboe Australia acquisition, to achieve planned economics or divest underperforming businesses; currency risk; adverse effect of new business activities; adverse effects from business divestitures; not being able to meet cash requirements because of our holding company structure and restrictions on paying inter-corporate dividends; dependence on third party suppliers and service providers; dependence of trading operations on a small number of clients; risks associated with our clearing operations; challenges related to international expansion; restrictions on ownership of TMX Group common shares; inability to protect our intellectual property; adverse effect of a systemic market event on certain of our businesses; risks associated with the credit of customers; cost structures being largely fixed; the failure to realize cost reductions in the amount or the time frame anticipated; dependence on market activity that cannot be controlled; the regulatory constraints that apply to the business of TMX Group and its regulated subsidiaries, costs of on exchange clearing and depository services, trading volumes (which could be higher or lower than estimated) and the resulting impact on revenues; future levels of revenues being lower than expected or costs being higher than expected.Forward-looking information is based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions with respect to the impact of the cost of acquisition financing on adjusted earnings per share; assumptions in connection with the ability of TMX Group to successfully compete against global and regional marketplaces and other venues; business and economic conditions generally; exchange rates (including estimates of exchange rates from Canadian dollars to the U.S. dollar, British pound sterling, or Australian dollar), commodities prices, the level of trading and activity on markets, and particularly the level of trading in TMX Group's key products; business development and marketing and sales activity; the continued availability of financing on appropriate terms for future projects; changes to interest rates and the timing thereof; productivity at TMX Group, as well as that of TMX Group's competitors; market competition; research and development activities; the successful introduction and client acceptance of new products and services; successful introduction of various technology assets and capabilities; the impact on TMX Group and its customers of various regulations; TMX Group's ongoing relations with its employees; and the extent of any labour, equipment or other disruptions at any of its operations of any significance other than any planned maintenance or similar shutdowns.In addition to the assumptions outlined above, forward looking information related to long term revenue CAGR objectives, and long term adjusted earnings per share CAGR objectives are based on assumptions that include, but not limited to:TMX Group's success in achieving growth initiatives and business objectives;continued investment in growth businesses and in transformation initiatives including next generation technology and systems;no significant changes to our effective tax rate, and number of shares outstanding;organic and inorganic growth in recurring revenuemoderate levels of market volatility over the long term;level of listings, trading, and clearing consistent with historical activity;economic growth consistent with historical activity;no significant changes in regulations;continued disciplined expense management across our business;continued re-prioritization of investment towards enterprise solutions and new capabilities;free cash flow generation consistent with historical run rate; anda limited impact from inflation, rising interest rates and supply chain constraints on our plans to grow our business over the long term including on the ability of our listed issuers to raise capital.While we anticipate that subsequent events and developments may cause TMX Group's views to change, TMX Group has no intention to update this forward-looking information, except as required by applicable securities law. This forward-looking information should not be relied upon as representing TMX Group's views as of any date subsequent to the date of this press release. TMX Group has attempted to identify important factors that could cause actual actions, events or results to differ materially from those current expectations described in forward-looking information. However, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended and that could cause actual actions, events or results to differ materially from current expectations. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. These factors are not intended to represent a complete list of the factors that could affect TMX Group. Important additional information identifying risks and uncertainties and other factors is contained in TMX Group's 2025 Annual Report under the headings entitled "Caution Regarding Forward-Looking Information" and "Enterprise Risk Management" which may be accessed at tmx.com in the Investor Relations section under Regulatory Filings.Non-GAAP Financial MeasuresThis press release includes references to financial measures that are not defined by GAAP. Although such non-GAAP measures are calculated according to accepted industry practice, such measures disclosed in this press release may be different from non-GAAP measures used by other companies. This data is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP. While TMX Group believes these measures provide investors with greater transparency and supplemental data relating to the transaction, readers are cautioned that these non-GAAP measures are not alternatives to measures determined in accordance with GAAP and should not, on their own, be construed as indicators of TMX Group's or Cboe Canada and Cboe Australia's future performance or profitability. Readers should not rely on any single financial measure when evaluating TMX Group's business or that of Cboe Canada and Cboe Australia. We use non-GAAP measures and non-GAAP ratios that do not have standardized meanings prescribed by GAAP and are, therefore, unlikely to be comparable to similar measures presented by other companies. Management uses these measures, and excludes certain items, because it believes doing so provides investors a more effective analysis of underlying operating and financial performance, including, in some cases, our ability to generate cash and our ability to repay debt. Management also uses these measures to more effectively measure performance over time, and excluding these items increases comparability across periods. The exclusion of certain items does not imply that they are non-recurring or not useful to investors.Adjusted earnings per share provided above is a non-GAAP ratio and does not have a standardized meaning prescribed by GAAP and is therefore unlikely to be comparable to similar measures presented by other companies. TMX Group presents Adjusted EPS and excludes, among other things, acquisition, integration, and related items; amortization of intangibles related to acquisitions; strategic re-alignment expenses; dispute, litigation and related items; and other items as disclosed in TMX Group's 2025 Annual Report. For more information on Adjusted EPS, including definitions and explanations of how these measures provide useful information, refer to Non-GAAP Measures in TMX Group's 2025 Annual Report.Adjusted EBITDA is calculated as net income excluding interest expense, income tax expense, depreciation and amortization, acquisition, integration, and related costs, one-time income (loss), and other significant items that are not reflective of the underlying business operations of Cboe Canada and Cboe Australia. Cboe Canada and Cboe Australia Adjusted EBITDA is a compilation of financial information provided to us for Cboe Canada and Cboe Australia entities as of December 31, 2025. The Cboe Canada and Cboe Australia financial information is unaudited and prepared in accordance with IFRS (Cboe Canada) or Australian Accounting Standards (Cboe Australia) for public companies. Adjusted EBITDA for Cboe Canada and Cboe Australia excludes certain items such as discontinued operations, transfer pricing, unrealized gains / losses, and one-time employee costs.About TMX Group (TSX: X) TMX Group operates global markets, and builds digital communities and analytic solutions that facilitate the funding, growth and success of businesses, traders and investors. TMX Group's key operations include Toronto Stock Exchange, TSX Venture Exchange, TSX Alpha Exchange, The Canadian Depository for Securities, Montréal Exchange, Canadian Derivatives Clearing Corporation, TSX Trust, TMX Trayport, TMX Datalinx, TMX VettaFi and TMX Newsfile, which provide listing markets, trading markets, clearing facilities, depository services, technology solutions, data products and other services to the global financial community. TMX Group is headquartered in Toronto and operates offices across North America (Montréal, Calgary, Vancouver and New York), as well as in key international markets including London, Singapore, and Vienna. For more information about TMX Group, visit www.tmx.com. Follow TMX Group on X: @TMXGroup.For more information please contact:Catherine KeeHead of Media RelationsTMX Group416-671-1704catherine.kee@tmx.comAmanda TangHead of Investor RelationsTMX Group416-895-5848amanda.tang@tmx.com To view the source version of this press release, please visit https://www.newsfilecorp.com/release/293729 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Apr 22, 2026 - (ACN Newswire via SeaPRwire.com) - Hengrui Pharma reported steady growth in the first quarter of 2026. In Q1 2026, the Company recorded revenue of RMB 8.14 billion, up 12.98% year-over-year, while net profit attributable to shareholders increased by 21.78% to RMB 2.28 billion. Innovative drugs remained the key growth driver, generating RMB 4.53 billion in revenue, up 25.75% year-over-year and accounting for 61.69% of total pharmaceutical sales.The Company continued to advance its innovation-driven strategy with sustained R&D investment and solid pipeline progress. R&D investments in Q1 2026 totaled RMB 2.22 billion, representing for approximately 27.32% of revenue.During the period, three innovative products and new indications were approved in China, which included an anti-PD-L1/TGF-βRII bi-functional fusion protein and an indication expansion for HER2-targeting ADC.In terms of pipeline advancement, the Company obtained 26 clinical trial approvals and had 8 new drug applications accepted in China across key therapeutic areas including oncology, metabolic, cardiovascular, and immunological diseases.Business development has become a recurring and increasingly important growth driver, with RMB 787 million in out-licensing revenue recognized during the quarter, primarily from the collaboration with GSK. Since 2023, Hengrui Pharma has completed 12 overseas business development transactions, including out-licensing, NewCo structures, and strategic alliance models.A key milestone during the period was the successful Nasdaq listing of Kailera Therapeutics (NASDAQ: KLRA), a NewCo company built around Hengrui Pharma’s GLP-1-based assets. This milestone reflects continued progress in executing the Company’s NewCo strategy, with Hengrui and Kailera working together to advance the global development of the GLP-1 portfolio.Looking ahead, Hengrui Pharma will remain committed to innovation and globalization, strengthening its pipeline and advancing the development and commercialization of innovative therapies to benefit patients worldwide. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月22日 - (亞太商訊 via SeaPRwire.com) - 4月22日晚，恒瑞醫藥發佈 2026年第一季度經營業績。2026年第一季度，公司實現營業收入81.41億元，同比增長12.98%；歸屬於於上市公司股東的淨利潤22.82億元，同比增長21.78%；歸屬於上市公司股東的扣除非經常性損益的淨利潤21.72億元，同比增長16.59%。2026年第一季度，公司創新藥銷售收入45.26億元，同比增長25.75%，佔藥品銷售收入的比重達61.69%。創新藥銷售收入中，抗腫瘤產品收入33.13億元，同比增長11.63%，佔整體創新藥銷售收入的73.20%。非腫瘤產品收入12.13億元，同比增長92.13%，佔整體創新藥銷售收入的26.80%。多款創新藥及新適應症獲批, 臨床研究高效推進公司持續加大創新力度，維持較高的研發投入，報告期內公司累計研發投入22.24億元，佔營業收入的27.32%，其中費用化研發投入16.51億元。在持續高強度研發投入的驅動下，恒瑞醫藥優質創新成果持續獲批，在研管線快速推進，創新研發成果加速轉化。在新藥和新適應症獲批方面，2026年以來，有3項創新成果獲批。首先，公司自主研發的1類創新藥、全球首款獲批上市的抗PD-L1/TGF-βRII雙特異性抗體融合蛋白瑞拉芙普α注射液（艾澤利(R)）獲批上市，聯合氟尿嘧啶類和鉑類藥物用於經充分驗證的檢測評估PD-L1陽性（CPS≥1）的局部晚期不可切除、復發或轉移性胃及胃食管結合部腺癌的一線治療。此外，公司自主研發的HER2 ADC、1類創新藥注射用瑞康曲妥珠單抗（艾維達(R)）新增適應症：本品適用於治療既往接受過一種或一種以上抗HER2藥物治療的局部晚期或轉移性HER2陽性成人乳腺癌患者。這是瑞康曲妥珠單抗（艾維達(R)）獲批上市的第2項適應症，也是在乳腺癌領域獲批的首個適應症，並在適應症獲批後一個月內，即被納入 2026中國臨床腫瘤學會乳腺癌診療指南，臨床價值獲得快速認可。同時，公司自主研發的1類創新藥海曲泊帕乙醇胺片（恒曲(R)）新增第三個適應症，用於重型再生障礙性貧血一線治療。在上市申報方面成果顯著，公司8項新藥上市申請獲受理（按品種適應症計），涵蓋腫瘤、代謝、心血管、免疫等疾病領域，包括去年首次獲批上市的創新藥磷羅拉匹坦帕洛諾司瓊（瑞坦寧(R)）用於預防中度致吐性抗腫瘤藥物引起的急性和遲發性噁心和嘔吐、瑞康曲妥珠單抗（艾維達(R)）用於HER2陽性結直腸癌。在臨床研發方面，公司一季度累計取得臨床試驗批准通知書26個（按品種適應症計）；2026年以來獲得CDE突破性治療品種認定6項，包括腫瘤創新產品HRS-4642注射液（KRAS G12D）和已上市的HER2 ADC瑞康曲妥珠單抗（艾維達(R)），以及非腫瘤創新產品HRS-5346片（Lp(a)）等。其中瑞康曲妥珠單抗已11次被納入突破性治療品種名單。NewCo模式成功落地，國際化再迎里程碑近年來，恒瑞醫藥持續構建開放合作的國際化生態，BD已成為常態化業務和新的增長引擎。一季度，創新藥對外許可業務確認收入7.87億元，主要系GSK確認的收入。自2023年起，恒瑞已完成12筆海外業務拓展交易，包括對外許可、NewCo和戰略聯盟等不同模式，合作物件包括GSK、默沙東等大型跨國藥企。近期，恒瑞醫藥國際化發展迎來新的里程碑。4月17日，公司合作夥伴Kailera Therapeutics公司（股票代碼：KLRA）成功在美國納斯達克交易所掛牌上市。這是恒瑞醫藥「NewCo」出海模式的成功實踐 - 驗證了全球化創新合作的高效路徑，標誌著恒瑞醫藥國際化發展再上新台階。2024年5月，恒瑞醫藥以「NewCo」模式將自主研發的GLP-1產品組合在除大中華區以外的全球範圍內開發、生產和商業化的獨家權利許可給Kailera，首付款加潛在里程碑付款累計可高達60億美元，公司還取得Kailera的部分股權。此後雙方共同努力，穩步推進GLP-1產品組合在海內外的開發落地。目前GLP-1/GIP雙受體激動劑瑞普泊肽（研發代號：HRS9531 ，大中華區外稱KAI-9531）在中國擬開發用於超重/肥胖及相關合併症、2型糖尿病等適應症，其中注射劑型用於成人長期體重管理的上市申請（NDA）已在中國獲受理。值得一提的是，在報告期內，口服瑞普泊肽已公佈中國Ⅱ期減重研究結果[1]，治療第26周時，參與者較基線平均體重下降最高達12.1%，且未觀察到平台期，同時嘔吐發生率不超過11.4%。口服瑞普泊肽計畫在中國推進肥胖症Ⅲ期臨床。口服小分子GLP-1受體激動劑HRS-7535擬開發用於超重/肥胖、2型糖尿病等適應症，其中2型糖尿病與超重或肥胖適應症均已在中國推進至Ⅲ期；GLP-1/GIP/GCG三重受體激動劑HRS-4729正在中國開展針對超重或肥胖的Ⅰ期臨床試驗，目前全球範圍內尚無同類產品上市。Kailera方面，目前正在開展瑞普泊肽注射液治療肥胖症的全球Ⅲ期臨床研究。HRS-7535（大中華區外稱KAI-7535）今年將啟動全球Ⅱ期臨床試驗，HRS-4729（大中華區外稱KAI-4729）將啟動全球Ⅰ期臨床試驗；口服瑞普泊肽則可能最早於2027年上半年啟動全球Ⅲ期臨床試驗。恒瑞醫藥表示，未來公司將繼續堅持自主研發與開放合作並重，持續探索多元化的創新國際合作模式，加速融入全球藥物創新生態、將更多優質創新藥品惠及全球患者。國際學術舞台頻頻亮相，多項臨床資料引關注 2026年以來，公司多項重磅臨床資料亮相國際知名學術會議，包括歐洲肺癌大會（ELCC）、美國癌症研究協會年會（AACR）、美國心臟病學會科學年會(ACC)、美國皮膚病學會年會（AAD）等。腫瘤領域，AACR大會重磅發表了公司肺癌領域研究成果。一項瑞康曲妥珠單抗單藥或聯合阿得貝利單抗一線治療HER2突變晚期非小細胞肺癌Ⅱ期研究結果顯示[2]，無論是單藥或聯合方案均展現出具有臨床意義的抗腫瘤活性，且無進展生存期呈持續獲益趨勢，整體安全性良好且可控。另一項阿得貝利單抗聯合化療圍術期治療可切除II-IIIB期非小細胞肺癌的III期臨床研究期中分析資料顯示[3]，該療法在主要終點病理緩解率和無事件生存期上均取得了統計學顯著且具有臨床意義的改善，安全性良好。基於該研究，阿得貝利單抗已於2025年遞交用於非小細胞肺癌相關治療的新適應症上市申請。非腫瘤領域，公司於ACC大會披露了新一代心肌肌球蛋白（Myosin）小分子抑制劑HRS-1893治療梗阻性肥厚型心肌病II期研究積極結果[4]，結果顯示HRS-1893可快速顯著降低左心室流出道壓差，在療效、安全性及給藥便利性方面具備潛在同類最佳臨床特徵。此外，公司自主研發的全球首創IL-23p19/IL-36R雙靶點抗體SHR-1139用於中重度斑塊狀銀屑病患者I期研究資料於AAD大會重磅發佈[5]，結果顯示SHR-1139在該患者群體中展現出具有臨床意義的獲益以及超長效作用特徵，同時安全性和耐受性良好。同時，公司有多項研究成果登上《臨床腫瘤學雜誌》、《英國醫學雜誌》、《美國醫學會心臟病學雜誌》等國際權威學術期刊。腫瘤領域，《臨床腫瘤學雜誌》重磅發表了CARES-005（CHANCE 2005） 研究。結果顯示[6]，與單純TACE治療相比，接受TACE聯合靶免（「雙艾」組合）治療的不可切除肝細胞癌（HCC）患者無進展生存期取得了具有臨床意義和統計學顯著性的改善，特別是納入的患者90%為高負荷、超40%為CNLC Ⅲa期（尤其合併Vp3-4門靜脈癌栓），補充了該治療策略的關鍵證據。基於進一步佈局的註冊Ⅲ期研究，「雙艾」組合聯合TACE治療不可切除HCC的上市許可申請已於2026年年初獲國家藥監局受理。同期，該刊還發表了瑞康曲妥珠單抗治療HER2表達的晚期胃/胃食管結合部腺癌和結直腸癌I期結果[7]，初步顯示出良好的抗腫瘤活性和安全性。非腫瘤領域，公司自主研發的ANGPTL3全人源單克隆抗體SHR-1918用於成人純合子家族性高膽固醇血症（HoFH）患者的Ⅱ期臨床研究發表於《美國醫學會心臟病學雜誌》。結果顯示[8]，每4週一次皮下注射 600mg SHR-1918可為HoFH受試者帶來顯著且持續的低密度脂蛋白膽固醇（LDL-C）降低（平均近60%降幅），並具有良好的安全性及耐受性。SHR-1918治療成人和12歲及以上的未成年人純合子家族性高膽固醇血症（HoFH）患者的上市申請已獲國家藥監局受理且被納入優先審評。憑藉高品質發展成效與持續創新，公司行業影響力持續提升。國際知名諮詢機構Citeline發佈的《Pharma R&D Annual Review 2026》顯示，恒瑞醫藥蟬聯自研管線數量全球第二；榮獲2026「中國傑出僱主」認證，這是公司連續5年獲此稱號，充分體現了公司在人才發展與組織建設方面的卓越表現。在持續高強度研發投入的驅動下，恒瑞醫藥將繼續堅持創新與國際化雙輪驅動戰略，深耕腫瘤、心血管與代謝、免疫與呼吸、神經科學四大核心治療領域，以創新助力「健康中國」，造福全球患者。參考文獻：[1] 根據研究資料整理.[2] Shun Lu,et al. 2026 AACR, Abs CT301[3] Yi-Long Wu, et al. Perioperative adebrelimab (A) plus chemotherapy (chemo) in resectable stage II-III NSCLC: Phase 3 EFS interim analysis (IA) and molecular residual disease (MRD) analysis. 2026AACR, CT014.[4] Efficacy And Safety Of BHB/HRS-1893 In Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From A 12-week Phase 2 Study. ACC.26. Late-Breaking Clinical Trials, Session 321, Featured Clinical Research V.[5] Xu JH, et al. A Randomized, Double-blind, Dose-Escalation, Placebo-Controlled Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-1139 for Patients with Moderate-to-Severe Plaque Psoriasis. Poster 75013, AAD 2026.[6] Zhu HD, Fan WJ, Zhao C, et al. Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial. J Clin Oncol. Published online February 24, 2026.[7] Liu T, Luo S, Yuan X, et al. Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial. J Clin Oncol. Published online March 4, 2026.[8] Peng D, Wang L, Pi L, et al. Anti-ANGPTL3 Antibody SHR-1918 for Homozygous Familial Hypercholesterolemia: A Nonrandomized Clinical Trial. JAMA Cardiol. 2026 Jan 7.  Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Apr 22, 2026 - (ACN Newswire via SeaPRwire.com) - Apr 20, Everest Medicines announced that the first-in-human (FIH) clinical trial data of EVM16, a proprietary personalized mRNA cancer vaccine, were presented at the 2026 American Association for Cancer Research  Annual Meeting (AACR 2026). The data include results from EVM16 as  a monotherapy and in combination with the PD-1 inhibitor tislelizumab in patients with advanced solid tumors. The results demonstrated that EVM16 has a favorable safety and tolerability profile, robust immunogenicity, and promising preliminary efficacy in patients with advanced solid tumors, supporting its further clinical development.The clinical trial (EVM16CX01, NCT06541639) was conducted jointly by Peking University Cancer Hospital and Fudan University Shanghai Cancer Center, with the first patient dosed in March 2025. EVM16CX01 is a first-in-human (FIH), dose-escalation, and expansion study evaluating the safety, tolerability, immunogenicity, and preliminary efficacy of EVM16 injection as a monotherapy and in combination with tislelizumab in patients with advanced solid tumors. The study follows a 3+3 dose-escalation design across three dose levels (0.1 mg, 0.3 mg, and 1.0 mg). Eligible patients are those with advanced or recurrent solid tumors who have failed standard of care and have at least one measurable target lesion. Patients receive 2 doses of EVM16 monotherapy once every two weeks, followed by combination therapy of EVM16 and tislelizumab. As of December 7, 2025, a total of 9 patients had been enrolled.No dose-limiting toxicities (DLTs) were observed. All patients experienced at least one investigational product (IP) related adverse event (AE), all of which were Grade ≤ 2 and resolved spontaneously. EVM16 elicited strong neoantigen-specific T cell responses in 8 of 9 patients, which showed a dose-dependent trend. A gastroesophageal junction cancer patient who failed 3 prior lines of systemic therapy achieved a confirmed partial response and a PFS of 126 days. Another 2 patients achieved stable disease. A non-small cell lung cancer patient who failed 3 prior lines of systemic therapy achieved a PFS of 88 days, and an esophageal squamous cell carcinoma patient who failed 3 prior lines of systemic therapy has been followed up for 112 days to date and has not experienced disease progression.“As a novel personalized mRNA cancer vaccine, EVM16 has demonstrated encouraging clinical development potential in its first-in-human clinical trial,” said Professor Shen Lin, Director of the Gastrointestinal Oncology Department at Beijing Cancer Hospital and Chair of the Gastric Cancer Expert Committee of the Chinese Society of Clinical Oncology. “The data show a favorable safety and tolerability profile in patients with advanced solid tumors, with no dose-limiting toxicities (DLTs) observed. Importantly, EVM16 stimulated neoantigen-specific T cell responses with a dose-dependent trend, highlighting its consistent immune activation capability. Preliminary anti-tumor activity signals, including partial response (PR) and stable disease (SD), were observed in patients who had failed multiple lines of standard-of-care therapies, suggesting potential clinical activity. These findings provide early clinical validation of EVM16 and reinforce its differentiated mechanism as a personalized mRNA cancer vaccine. While immunotherapies, including checkpoint inhibitors, have transformed the treatment landscape in selected tumor types, most patients, particularly those with heavily pretreated advanced solid tumors, still represent a significant unmet medical need. Personalized mRNA cancer vaccines represented by EVM16 may help expand the population benefiting from immunotherapy and provide additional treatment options.” “The favorable safety, tolerability, immunogenicity, and preliminary efficacy results for EVM16 provide initial evidence of its therapeutic potential and support the clinical value of our in-house mRNA platform,” said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Patients with advanced solid tumors, particularly those who have failed multiple lines of therapy, continue to suffer from limited treatment options. As our first in-house developed personalized mRNA cancer vaccine, EVM16 demonstrates the ability to induce immune activation and generate neoantigen-specific T cell responses, which may help reduce the risk of tumor metastasis or recurrence. This further underscores its potential as a novel approach in cancer immunotherapy. This project is powered by EVER-NEO-1, Everest’s proprietary AI-based neoantigen prediction algorithm. It analyzes patient-specific tumor mutations to identify highly immunogenic neoantigens and support the design of personalized mRNA vaccine candidates. The algorithm incorporates iterative learning capabilities designed to continuously improve neoantigen prediction accuracy and selection efficiency. Leveraging our leading mRNA platform, we will continue to advance the clinical development of EVM16 and bring this innovative therapy to more patients.”Everest Medicines has localized its clinically validated proprietary AI+mRNA platform, establishing an end-to-end integrated platform spanning antigen design, mRNA sequence optimization, lipid nanoparticles (LNP) targeted delivery and scalable manufacturing, with the potential to address significant unmet medical needs globally.EVM16 is a novel personalized therapeutic mRNA cancer vaccine in-house developed by Everest. It contains neoantigens with high immunogenicity potential, predicted based on the unique tumor mutations of each patient using Everest’s proprietary AI-based neoantigen prediction algorithm, EVER-NEO-1. The vaccine is designed to encode dozens of tumor neoantigens. The vaccine uses a lipid nanoparticle (LNP) delivery system to efficiently deliver neoantigen-encoded mRNA in vivo, activating neoantigen-specific tumor-killing T cells and inhibiting tumor growth.From an investment and market perspective, personalized cancer vaccines are in an early stage of breakthrough. According to Grand View Research, the global personalized cancer vaccine market is projected to reach $1.45 billion by 2030, with a staggering compound annual growth rate (CAGR) of 44.86% from 2025 to 2030. Myguide Securities points out that mRNA cancer vaccines have the potential to achieve pan-cancer coverage while offering the advantages of high accessibility, “off-the-shelf” availability, and personalization. As a highly promising new form of immunotherapy, it can enter clinical use as adjuvant therapies through extensive combinations, gradually unlocking a market space worth tens of billions of dollars.Against this backdrop, Everest Medicines is accelerating its strategic positioning in this field, progressively building a research and development pipeline with global competitiveness. Leveraging its proprietary AI+mRNA platform and its leading clinical position in China, Everest Medicines is currently at a critical juncture for industrialization and valuation growth. The upcoming readout of first-in-human (FIH) clinical trial data for EVM16 is expected to further release clinical and commercial potential, continuing to attract focus from the market and investors, and helping the company achieve a significant leap in value within the immunotherapy sector. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年4月22日 - (亞太商訊 via SeaPRwire.com) - 4月20日，雲頂新耀宣佈在2026年美國癌症研究協會（AACR）年會上公佈其自主研發的mRNA個性化腫瘤治療性疫苗EVM16單藥治療及聯合PD-1抑制劑（替雷利珠單抗）治療晚期實體瘤的首次人體臨床試驗（FIH）數據。結果顯示出良好的安全性和耐受性、顯著的免疫原性及積極的初步療效信號，支持進一步臨床開發的推進。據悉，該臨床試驗由北京大學腫瘤醫院與復旦大學附屬腫瘤醫院聯合發起（EVM16CX01，NCT06541639），並於2025年3月完成首例患者給藥。EVM16CX01是一項評估EVM16注射液單藥及聯合PD-1抑制劑治療對晚期或復發實體瘤患者的安全性、耐受性、免疫原性和初步療效的劑量遞增及擴展研究，該試驗採用3+3 劑量遞增設計，包括三個劑量組：0.1 mg、0.3 mg和1.0 mg。入選患者為經標準治療失敗的晚期或復發性實體瘤患者，且至少有一個可測量靶病灶。患者將接受2次EVM16單藥治療（每兩週一次），隨後接受EVM16聯合替雷利珠單抗治療。截至2025年12月7日，共入組9例患者。安全性和耐受性方面，EVM16未觀察到劑量限制性毒性（DLT）。所有患者均報告至少一次與研究藥物相關的不良事件，均為2級及以下，且均可自行緩解。 EVM16在9例患者中有8例誘導出強烈的新抗原特異性T細胞免疫反應，並顯示出劑量依賴性趨勢。初步臨床療效方面，一例既往接受過三線系統治療失敗的胃食管結合部癌患者達到確認的部分緩解（PR），無進展生存期（PFS）為126天。另有2例患者達到疾病穩定(SD)，其中一例既往接受過三線系統治療失敗的非小細胞肺癌患者PFS為88天，另一例既往接受過三線系統治療失敗的食管鱗癌患者截至數據截止日已隨訪112天，尚未觀察到疾病進展。北京大學腫瘤醫院消化腫瘤內科主任、中國臨床腫瘤學會胃癌專家委員會主任委員沈琳教授表示：「EVM16作為一款新型mRNA個性化腫瘤治療性疫苗，在首次人體臨床試驗中展現出良好的臨床開發潛力。數據顯示，該疫苗在晚期實體瘤患者中整體安全性與耐受性良好，未觀察到劑量限制性毒性。在免疫學層面，EVM16能夠誘導新抗原特異性T細胞應答，並呈現一定劑量依賴趨勢，提示其具有較強的免疫啟動能力。在療效探索方面，臨床試驗在既往接受多線標準治療失敗的患者中觀察到初步抗腫瘤活性信號，包括部分緩解（PR）及疾病穩定（SD），顯示其免疫學作用機制具有改善臨床獲益的潛力。總體而言，該臨床試驗初步驗證了EVM16通過新抗原驅動T細胞應答實現腫瘤免疫啟動的臨床價值，為其後續臨床開發提供了重要依據。當前，儘管免疫檢查點抑制劑已顯著改善部分腫瘤的治療格局，但總體獲益人群仍有限，尤其是在多線治療失敗的晚期實體瘤患者中仍存在顯著未滿足需求。EVM16所代表的mRNA個性化腫瘤治療性疫苗治療路徑，有望在現有免疫治療基礎上進一步拓展受益人群，並帶來更多治療選擇。」雲頂新耀首席執行官羅永慶表示：「非常高興看到EVM16的首次人體臨床試驗數據在AACR大會上公佈。此次公佈的在晚期實體瘤患者中展現出良好的安全性與耐受性、療效及作用機制等方面的積極結果，初步驗證了EVM16的治療潛力和雲頂新耀自研mRNA平台的臨床價值。對於晚期實體瘤患者而言，尤其是多線治療失敗人群，仍然缺乏有效且具有針對性的治療選擇。EVM16作為公司自主研發的mRNA個性化腫瘤治療性疫苗，具備誘導免疫啟動並產生新抗原特異性T細胞應答的潛力，有望預防腫瘤轉移或復發，代表了腫瘤免疫治療的重要探索方向。該項目基於公司自主研發的EVER-NEO-1『妙算』腫瘤新抗原人工智慧演算法系統。該系統可基於患者腫瘤特異性突變進行分析，識別具有較高免疫原性的腫瘤新抗原，並生成相應的mRNA疫苗設計方案，且具備自我迭代優化能力，以持續提升新抗原預測與篩選效率。依託國際領先的mRNA平台，我們將加速推進EVM16後續臨床開發工作，推動該創新療法惠及更多患者。」雲頂新耀已成功將經過臨床驗證的自研AI+mRNA平台本地化，構建了一個涵蓋從抗原設計、mRNA序列優化、脂質納米顆粒（LNP）靶向遞送技術到產業化生產的端到端全產業鏈平台，具備了在全球範圍內解決巨大未滿足醫療需求的潛力。EVM16是公司自主研發的mRNA個性化腫瘤治療性疫苗，根據每位患者特有的腫瘤細胞突變，通過EVER-NEO-1「妙算」系統識別具有較高免疫原性的腫瘤新抗原，並設計編碼數十種腫瘤新抗原的mRNA治療性疫苗。EVM16通過LNP靶向遞送系統在體內進行高效的抗原呈遞，啟動患者自身的新抗原特異性T細胞免疫，進而達到殺傷腫瘤細胞和治療癌症的目的。從投資與市場維度來看，個體化腫瘤疫苗尚處早期突破期。根據Grand View Research的預測，全球個性化癌症疫苗市場規模2030年將達14.5億美元，2025-2030年複合增長率高達44.86%。麥高證券指出，mRNA腫瘤疫苗有望實現泛癌種覆蓋，同時兼具高可及性、現貨化與個性化優勢。作為極具潛力的新型腫瘤免疫療法，其可通過廣泛聯用，以輔助療法切入臨床，逐步打開數百億美元的市場空間。在此背景下，雲頂新耀在該領域的佈局正加速落地，逐步構建具備全球競爭力的研發管線。依託自主AI+mRNA平台與國內率先佈局的臨床身位，雲頂新耀正處於產業化與估值成長的關鍵節點。本次EVM16首次人體臨床試驗（FIH）數據的讀出，有望進一步釋放臨床與商業化潛力，進一步吸引市場及投資者持續聚焦，助力公司在腫瘤免疫賽道實現長足的價值跨越。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com